Vu Dinh Hoa, PhD A/Prof is Deputy Director of National Drug Information and Adverse Drug Event Monitoring Center of Viet Nam. He is also the lecturer in Hanoi University of Pharmacy and adjunct researcher at Vietnam National Children Hospital. His research of interest focus on optimizing the use of of antimicrobial agents including antibiotics, antifungal and antituberculosis drug based on PK/PD. He also have experience in dried blood spot for antituberculosis drugs, and therapeutic drug monitoring. He is supervising TDM teams in numbers of hospitals to develop TDM service for vancomycin and amikacin. His research team is working on the Model Informed Precision Dosing (SmartDoseAI®) for vancomycin using a web-based platform. He is also working with the Intensivists and Pediatricians to guide the antimicrobial treatment for critically ill patients, patients on Renal Replacement Therapy, neonates and paediatrics. He is an active member of the Regional Asian Paciffic Section of the International Association of TDM and Clnical Toxicology.

Pieter De Cock is an Associate Professor in Clinical Pharmacology at the Faculty of Medicine and Health Sciences at Ghent University, Belgium, and a hospital pharmacist–clinical pharmacologist at Ghent University Hospital. At Ghent University, Pieter De Cock leads the Ghent Precision Dosing Research Unit, which focuses on (i) pharmacokinetic/pharmacodynamic (PK/PD) clinical research in special patient populations and, (ii) the clinical implementation of model-informed precision dosing (MIPD) tools. Currently, he is the principal investigator on three randomized clinical trials evaluating the added value of MIPD for anti-infective therapies. As a clinical pharmacist and member of the dosing advisory service at the hospital pharmacy of Ghent University Hospital, he is also involved in the day-to-day optimization of TDM-based dosing.

Anne-Grete Märtson is an assistant professor at the Leiden Academic Centre for Drug Research, Leiden University. She is leading a research group focusing on translational antiviral pharmacology. The group focuses on clinical studies, laboratory experiments such as the hollow fibre infection model and use computational methods to find best treatment regimens and translate results back to the clinical setting. The research topics include optimizing ganciclovir therapy for cytomegalovirus (CMV), therapeutic drug monitoring of antivirals, relating antiviral drug exposure to dose-related toxicity, dosing in extremes of organ function and in special populations, delay in antiviral therapy in SARS-CoV-2.

Dr. Mangalore is an Infectious Disease Physician and clinical researcher at Alfred Health and Monash University. Her research focuses on personalised antibiotic dosing using therapeutic drug monitoring and model-informed precision dosing to improve patient outcomes in critically ill patients. Dr Mangalore leads the beta-lactam TDM program at Alfred Health.